Roivant Expects FDA to Approve First Major Drug

Roivant Chief Executive Officer Matt Gline expects the FDA to approve the launch of a drug used to fight a debilitating skin disease. He says the drug should be on the market by September. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.